INTELLIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.76 USD | +3.70% |
|
-3.76% | -31.91% |
| 04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
| 03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Chart calendar Intellia Therapeutics, Inc.
f9.Ae9HZPvZQbfZ-7X-hq2BU9Nnbon-FPdXJbmovjnhoUI.NbUjHKrpdOa3wsXG9PrXG-c1Hei0QZgNUo6c0QuM8SpKlXAmg7Qtx5Cq3g~1cb7cfa5ba243ab9e2f30ff5d339651c
Upcoming events on Intellia Therapeutics, Inc.
Past events on Intellia Therapeutics, Inc.
| 13/03/2024 19:05 | Barclays Global Healthcare Conference |
| 12/03/2024 17:00 | Leerink Partners Global Biopharma Conference |
| 03/03/2024 | TD Cowen Health Care Conference |
| 22/02/2024 13:00 | Q4 2023 Earnings Call |
| 22/02/2024 12:30 | Q4 2023 Earnings Release |
| 10/01/2024 01:15 | JPMorgan Healthcare Conference |
| 15/11/2023 08:00 | Jefferies London Healthcare Conference |
| 09/11/2023 13:00 | Q3 2023 Earnings Call |
| 09/11/2023 12:30 | Q3 2023 Earnings Release |
| 02/11/2023 10:30 | International ATTR Amyloidosis Meeting |
| 09/10/2023 | Cell & Gene Meeting on the Mesa Conference |
| 26/09/2023 | Cantor Global Healthcare Conference |
| 25/09/2023 | BMO Gene Editing Conference |
| 06/09/2023 15:15 | Wells Fargo Healthcare Conference |
| 03/08/2023 13:00 | Q2 2023 Earnings Call |
| 03/08/2023 12:30 | Q2 2023 Earnings Release |
| 14/06/2023 14:00 | Annual General Meeting |
| 12/06/2023 13:00 | NTLA 2022 Phase 1/2 Interim Clinical Data Study Results Call |
| 11/06/2023 13:30 | European Academy of Allergy and Clinical Immunology Hybrid Congress |
| 30/05/2023 16:30 | Stifel Tailoring Genes Genetic Medicines Day |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 43,1 42,1 2.39% | 58,0 66,8 -13.13% | 33,1 29,2 13.37% | 52,1 50,0 4.21% | 36,3 50,0 -27.51% | 50,2 |
|
EBITDA Million USD | Released Forecast Spread | -101 -105 3.93% | -130 -134 2.56% | -261 -259 -0.86% | -451 -434 -3.94% | -506 -482 -5% | -509 |
|
EBIT Million USD | Released Forecast Spread | -106 -106 -0.58% | -137 -131 -4.35% | -268 -261 -2.66% | -458 -450 -1.8% | -515 -511 -0.9% | -529 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -99,5 -99,0 -0.49% | -134 -126 -6.56% | -268 -259 -3.57% | -474 -465 -1.97% | -481 -478 -0.72% | -523 |
|
Net income Million USD | Released Forecast Spread | -99,5 -99,0 -0.49% | -134 -126 -6.56% | -268 -254 -5.62% | -474 -463 -2.33% | -481 -475 -1.24% | -512 |
|
EPS USD | Released Forecast Spread | -2,11 -2,10 -0.66% | -2,40 -2,27 -5.73% | -3,78 -3,63 -4.01% | -6,16 -6,13 -0.52% | -5,42 -5,40 -0.44% | -5,53 |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 12,6 7,83 60.77% | 11,3 8,57 31.31% | 14,0 9,50 47.7% | 13,3 10,9 21.37% | 13,6 10,7 26.72% | 12,6 11,1 13.35% | 13,6 11,3 20.14% | 12,0 12,0 0.32% | -1,92 11,4 -116.88% | 9,07 | 19,1 | 9,76 | 9,53 | 17,7 |
|
EBITDA Million USD | Released Forecast Spread | -104 -76,2 -35.93% | -108 -102 -6.33% | ||||||||||||
|
EBIT Million USD | Released Forecast Spread | -80,4 -71,4 -12.62% | -144 -83,7 -72.41% | -98,3 -94,8 -3.71% | -106 -105 -0.5% | -110 -110 0.04% | -112 -118 5.13% | -132 -120 -10.21% | -131 -139 5.42% | -140 -137 -2.47% | -135 | -129 | -140 | -144 | -145 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -81,2 -69,4 -17.04% | -147 -85,0 -72.82% | -101 -93,6 -7.56% | -113 -105 -8.16% | -113 -110 -3.43% | -103 -116 11.31% | -124 -115 -7.76% | -122 -134 8.73% | -132 -132 0.07% | -127 | -124 | -133 | -138 | -140 |
|
Net income Million USD | Released Forecast Spread | -81,2 -69,4 -17.05% | -147 -83,2 -76.58% | -101 -92,6 -8.77% | -113 -105 -8.16% | -113 -109 -4.41% | -103 -115 10.57% | -124 -115 -7.38% | -122 -133 8.15% | -132 -130 -1.91% | -125 | -121 | -131 | -136 | -140 |
|
EPS USD | Released Forecast Spread | -1,09 -0,94 -15.87% | -1,96 -1,10 -77.8% | -1,33 -1,31 -1.7% | -1,49 -1,25 -19.52% | -1,38 -1,36 -1.33% | -1,17 -1,37 14.79% | -1,40 -1,31 -7.12% | -1,38 -1,50 8.12% | -1,46 -1,43 -1.82% | -1,37 | -1,27 | -1,40 | -1,43 | -1,41 |
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 09/11/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for Intellia Therapeutics, Inc.
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 06:00 | BB BIOTECH AG: Q1 2024 Earnings Release |
| 25/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 25/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 25/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 12:00 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 07:00 | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NTLA Stock
- Calendar Intellia Therapeutics, Inc.
